Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476465 | 0.84 | MAPK1 (0.42) | MAPK1MTNR1ADRD2 | |
| SCHEMBL4369638 | 0.74 | SLC2A1 (0.33) | MTNR1ASLC2A1POLBLMNAMAPT | |
| SCHEMBL4369653 | 0.74 | SLC2A1 (0.33) | MTNR1ASLC2A1POLBLMNAMAPT | |
| SCHEMBL4369650 | 0.74 | SLC2A1 (0.33) | MTNR1ASLC2A1POLBLMNAMAPT | |
| SCHEMBL4369636 | 0.74 | SLC2A1 (0.33) | MTNR1ASLC2A1POLBLMNAMAPT | |
| SCHEMBL10025493 | 0.69 | MTNR1A (0.34) | MTNR1ADRD2HTR1ADRD1HTR1B | |
| SCHEMBL8131743 | 0.64 | HTR1A (0.64) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL10829330 | 0.61 | MAPK1 (0.50) | MAPK1MTNR1APOLBDRD2 | |
| SCHEMBL2247241 | 0.59 | SIGMAR1 (0.52) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL18717468 | 0.59 | ESR1 (0.48) | SLC2A1POLBMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085475-A1 | Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9,-trioxa-3-aza-cyclopenta[a]naphthalene as 5-ht1a antagonists | WYETH (US) | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085475-A1 | Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9,-trioxa-3-aza-cyclopenta[a]naphthalene as 5-ht1a antagonists | HTR1A, HTR5A, HTR1B | MAPK1 3707/4885MTNR1A 24/4885SLC2A1 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.